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Abstract
Background: Enhanced expression of MAdCAM-1 (mucosal addressin cell adhesion molecule-1)
is associated with the onset and progression of inflammatory bowel disease. The clinical significance
of elevated MAdCAM-1 expression is supported by studies showing that immunoneutralization of
MAdCAM-1, or its ligands reduce inflammation and mucosal damage in models of colitis.
Interleukin-10 (IL-10) is an endogenous anti-inflammatory and immunomodulatory cytokine that
has been shown to prevent inflammation and injury in several animal studies, however clinical IL-
10 treatment remains insufficient because of difficulties in the route of IL-10 administration and its
biological half-life. Here, we examined the ability of introducing an IL-10 expression vector into
endothelial cultures to reduce responses to a proinflammatory cytokine, TNF-α
Methods: A human IL-10 expression vector was transfected into high endothelial venular ('HEV')
cells (SVEC4-10);  we then examined TNF-α induced lymphocyte adhesion to lymphatic endothelial
cells and TNF-α induced expression of MAdCAM-1 and compared these responses to control
monolayers.
Results: Transfection of the IL-10 vector into endothelial cultures significantly reduced TNF-α
induced, MAdCAM-1 dependent lymphocyte adhesion (compared to non-transfected cells). IL-10
transfected endothelial cells expressed less than half (46 ± 6.6%) of the MAdCAM-1 induced by
TNF-α (set as 100%) in non-transfected (control) cells.
Conclusion: Our results suggest that gene therapy of the gut microvasculature with IL-10 vectors
may be useful in the clinical treatment of IBD.
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Background
Endothelial cell adhesion molecules ('ECAMs') play es-
sential roles in the development of chronic inflammation
by recruiting leukocytes, especially lymphocytes to tissues.
ECAMs support several forms of leukocyte adhesion in-
cluding rolling, firm adhesion and extravasation [1]. Infil-
tration of tissues by leukocytes is a common hallmark of
many chronic inflammatory states that include the in-
flammatory bowel diseases (IBD), ulcerative colitis (UC),
and Crohn's disease (CD). In the setting of IBD, the ex-
pression of ECAMs like ICAM-1, VCAM-1, and MAdCAM-
1 (mucosal addressin cell adhesion molecule-1) is ob-
served in experimental models of colitis, [2–5] and also
within the inflamed human colon in Crohn's disease and
ulcerative colitis [6,7].
Among the adhesion molecules up-regulated in IBD,
MAdCAM-1, the mucosal cell adhesion molecule, is
thought to be preeminent in the development of chronic
gut inflammation. MAdCAM-1 is normally expressed in
the gut, and its expression is dramatically amplified dur-
ing inflammation [2,3]. The functional significance of in-
creased appearance of MAdCAM-1 in IBD is supported by
several reports which show that immunoneutralization of
either MAdCAM-1 or its ligand, the α4β7 integrin, attenu-
ate inflammation and mucosal damage in animal models
of colitis [8–10]. However, since monoclonal antibodies
directed against other ECAMs, particularly VCAM-1, can
as well reduce disease activity in colitis models [11–14],
the literature suggests that MAdCAM-1 is probably neces-
sary, but insufficient for the maximal penetrance of exper-
imental and probably also clinical IBD.
Based on these findings, it is apparent that a better under-
standing of the mechanisms regulating ECAM expression,
especially that of MAdCAM-1, might help to devise im-
proved therapies for colitis.
It has been suggested that pathologic activation of the mu-
cosal immune system in response to antigens is a key fac-
tor in the pathogenesis of IBD. Furthermore, changes in
leukocyte migration and cytokine production appear to
contribute the perpetuation of IBD [15]. Based on mod-
ern advances, recombinant anti-inflammatory cytokines
(i.e. IL-10) treatment is now being developed for experi-
mental colitis and human IBD. IL-10 produced by macro-
phages and monocytes appears to limit chronic
inflammation [16–18], through a decreased release of in-
flammatory factors (IL-1, IL-6, IL-12, TNF-α, GM-CSF,
GCSF), suppression of adhesive determinants (MHC class
II molecule, β7), and by blocking ICAM-1 induction [19–
24].
Conversely, IL-10 gene-knockout mice develop a chronic
colitis that is extremely similar to IBD [25]. IL-10 treat-
ment can reduce inflammation in several models of colitis
[26–30] and human IBD [31–35]. However, the clinical
efficacy of systemically administered IL-10 for patients
mild to moderately active Crohn's disease has not been as
effective as hoped [33–35]. Furthermore the efficacy of IL-
10 administration in mouse colitis models is contentious
[36].
We have described in vitro that exogenous IL-10 can block
the expression of MAdCAM-1 in response to TNF-α, and
attenuates lymphocyte adhesion to lymphatic node de-
rived endothelium under cytokine stimulating conditions
via NF-kB inhibition [5]. The purpose of the current study
was to show that induction of endothelial expression of
IL-10 through an IL-10 expression vector attenuates MAd-
CAM-1 expression in response to TNF-α and optimistical-
ly suggests the possibility of targeted Th2-cytokine gene
therapy in IBD.
Methods
Reagents
Recombinant mouse TNF-α was purchased from EN-
DOGEN (Stoughton, MA) amd plasmid containing hu-
man IL-10 (phIL-10) was generous gift from Dr. Meng X
(Thomas Jefferson University, PA).
Cell culture
The SVEC4-10 line is an endothelial cell line derived by
SV40 (strain 4A) transformation of murine small vessel
endothelial cells, originally isolated from the axillary
lymph node vessels of an adult male C3H/Hej mouse
[37,38]. These cell types were all maintained in Dulbec-
co's modified Eagle's medium (DMEM) with 10% fetal
calf serum with 1% antibiotic/ antimycotic. Cells were
seeded into 24-well tissue culture plates at approximately
20,000 cells/cm2, and cultures were used immediately
upon reaching confluence (usually 3–4 days after
seeding).
Lymphocytes
The mouse CD8+ T cell lymphoma TK-1 cells (that consti-
tutively expresses the α4β7 integrin [39]) were obtained
as a generous gift from Dr. Eugene Butcher (Stanford Uni-
versity, CA). These cells were cultured in RPMI-1640 me-
dium supplemented with 10% FCS and 0.05 mM 2-
mercaptoethanol (minus antibiotic/ antimycotic).
IL-10 gene transfer
The pCYIL-10 vector is an expression vector which was es-
tablished by Dr. Xianmin Meng based on the pCY4B vec-
tor [40]. Cultured SVEC endothelial cells seeded in 24
wells were transfected at 70% confluency with SuperFect
(Qiagen). Briefly, 1 µg plasmid DNA was diluted with 60
µl DMEM and then 5 µl Superfect (3 mg/ml) was added.
After incubation at room temperature for 10 min, theBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/3
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complex was mixed with 350 µl medium and added to the
each wells. After 2 h at 37°C, 5% CO2, the complex was
aspirated and washed 2 times with medium following re-
place by 1 ml of medium. After incubation at 37°C for 24
h cells were stimulated with TNF-α.
Western analysis of cell lysates
24 h of IL-10 gene transfer, monolayers were treated with
TNF-α (1 ng/ml, 24 h). All cell samples were harvested at
24 hours. Equal quantities of protein (75 µg) from each
sample were electrophoretically separated on 7.5% SDS-
PAGE gels. Gels were transferred to nitrocellulose mem-
branes (Sigma) and blocked with 5% milk powder in PBS
at 4°C (overnight). These membranes were washed twice
for 10 min with wash buffer (0.1% milk powder in PBS).
Primary rat anti-mouse MAdCAM-1 mAb was added at a
concentration of 10 µg/ml and incubated at room temper-
ature for 2 h. These membranes were washed twice with
wash buffer. Secondary rabbit anti-rat horseradish peroxi-
dase conjugated secondary antibody (Sigma) was added
at a 1:2000 dilution for 2 h. Lastly, membranes were
washed 3 times and developed using the enhanced chemi-
luminescence (ECL) detection system (Amersham, La Jol-
la, CA). The density of MAdCAM-1 staining was measured
by scanning the 60 kD band, using a HP ScanJet™ flatbed
scanner. Images were analyzed for density using Image
Pro Plus™ image analysis software (Media Cybernetics).
The data are expressed as a percentage of TNF-α-induced
level of density. In each protocol, treatments were per-
formed at least in triplicate.
TK-1 lymphocyte adhesion assay
Briefly, TK-1 cells were suspended in culture medium and
fluorescence labeled by incubating TK-1 cells at 2 × 10 6
cells/ml with 0.02 mg fluorescein diacetate (FDA) (Sig-
ma) at 37°C for 30 min. The cells were then washed twice
with ice-cold HBSS, spun at 250 g for 5 min to remove un-
incorporated fluorescence and suspended in HBSS. The
TK-1 lymphocyte cell line used in this assay expresses high
levels of the α4β7 integrin, [39,41] which can interact
with multiple ligands including mucosal addressin-1
(MAdCAM-1), as well as VCAM-1, L-selectin and fibronec-
tin [42]. In this system, TNF-α stimulated TK-1 adhesion
to SVEC4-10 endothelial cells is at least 50% MAdCAM-1
dependent [41]. SVEC monolayers were grown in 48-well
plates as described, and to activate endothelium, the mon-
olayers were incubated with TNF-α (1 ng/ml) for 24 h. Cy-
tokine treated endothelial cells were washed three times
with media. Labeled TK-1 cells were then added to the en-
dothelium at a 5:1 lymphocyte to endothelial cell ratio
[43] and allowed to bind for 30 min under static condi-
tions. At the end of the incubation period, the supernatant
was removed and the monolayers were washed twice with
HBSS. Plates were read on a Fluoroskan Ascent (Labsys-
tems, Helsinki, Finland) set for excitation at 485 nm, and
emission at 515 nm. Blank wells (0% TK-1 adhesion)
were run as controls that did not contain labeled TK-1
cells. The data are expressed as a percentage of TNF-α-in-
duced level of fluorescence. In each protocol, treatments
were performed at least in triplicate.
Statistical analysis
All values are expressed as mean ± SD. Data were analyzed
using multiple comparisons. Probability (P) values of <
0.05 were considered significant.
Results
Secretion of human IL-10 concentration by transfected en-
dothelial cells
To screen for the efficacy of IL-10 transfected SVEC, we in-
itially measured the IL-10 concentration in the medium
prior to gene transfection. There was no detectable human
IL-10 signal in the non-transfected cell medium (control),
nor any mouse IL-10 (data not shown). However, the me-
dium from the IL-10 transfected SVEC medium showed a
large and significant increase in the IL-10 concentration
(1209 ± 2 pg/ml) at 48 h after IL-10 gene transfection (Fig-
ure 1). Importantly, SVEC cells transfected with this vector
showed no evidence of toxicity, altered proliferation and
morphologically were indistinguishable from mock-
transfected and untreated controls.
Figure 1
Secretion of human IL-10 concentration by trans-
fected endothelial cells. There was no detectable human 
IL-10 signal in the non-transfected cell medium (control). 
However, the medium from the IL-10 transfected SVEC 
medium showed a large and significant increase in the IL-10 
concentration (1209 ± 2 pg/ml) at 48 h after IL-10 gene 
transfection (n = 5). (# p < 0.05 from control). One-way 
ANOVA with Fisher's PLSD test.
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MAdCAM-1 expression in IL-10 gene transfected endothe-
lial cells
The anti-inflammatory effect of IL-10 gene transfection in
endothelial cells was measured by the reduction in the ex-
pression of the endothelial cell adhesion molecule MAd-
CAM-1 induced by TNF-α (1 ng/ml, 24 h). TNF-α strongly
induced expression of MAdCAM-1. This effect was signifi-
cantly reduced by IL-10 gene transfection (Fig. 2). Alone,
the IL-10 gene transfection had no effect on MAdCAM-1
expression.
α4β7 integrin lymphocyte adhesion to IL-10 gene trans-
fected endothelial cells
Having established that IL-10 gene transfection exerts a
significant protective effect against TNF-α stimulated en-
dothelial MAdCAM-1 induction, we next examined the ef-
fects of IL-10 gene transfection on the adhesion of α4β7
expressing lymphocytes (using the mouse cell line TK-1)
to endothelial monolayers. TNF-α stimulation (1 ng/ml,
24 h) significantly increased the adhesion of TK-1 lym-
phocytes to SVEC monolayers. IL-10 gene transfection sig-
nificantly reduced TK-1 adhesion in response to TNF-α
stimulation at 24 h (Fig. 3). Alone, IL-10 gene transfection
did not modify the basal level of lymphocyte adhesion to
the endothelium without TNF-α treatment.
Discussion
MAdCAM-1 is a 60 kDa endothelial cell surface molecule
that is strongly expressed by mucosal endothelial cells,
particularly following exposure of these cells to pro-in-
flammatory cytokines such as TNF-α. Expression of MAd-
CAM-1 has also been reported in the brain, and in the
heart [44,45]; based on these findings, it is now been
suggested that MAdCAM-1 might play roles in chronic in-
flammation of these organs as well.
With respect to inflammatory bowel disease, MAdCAM-1
appears to be essential to the lymphocyte homing to the
mucosa associated lymphoid tissue (MALT) [6,37,38,46].
Since MAdCAM-1 is normally expressed mainly within
the gut microvasculature, and is dramatically amplified
during IBD, it has been suggested that increased MAd-
CAM-1 expression contributes to the etiology of IBD
through its ability to direct homing of lymphocytes to the
gut. This notion is well supported by several reports that
show that antibodies directed against either MAdCAM-1,
or its lymphocyte ligand, the α4β7 integrin will
significantly attenuate several indices of gut damage in ex-
perimental models of colitis [9,47].
Figure 2
IL-10 gene transfected SVEC is resistant to TNF-α 
induced MAdCAM-1 expression. TNF-α (1 ng/ml, 24 h) 
significantly increased expression of MAdCAM-1 and this was 
significantly blocked by IL-10 gene transfection. Alone, IL-10 
gene transfer had no effect on MAdCAM-1 expression (n = 
5). (* p < 0.05 from TNF-α, # p < 0.05 from control). One-
way ANOVA with Fisher's PLSD test.
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Figure 3
IL-10 gene transfer blocked TNF-α induced lym-
phocyte adhesion on SVEC. TNF-α stimulation (1 ng/ml, 
24 h) significantly increased the adhesion of TK-1 lym-
phocytes to SVEC monolayers. IL-10 gene transfer signifi-
cantly reduced TK-1 adhesion in response to TNF-α 
stimulation at 24 h. IL-10 gene transfer did not modify the 
basal level of lymphocyte adhesion to the endothelium with-
out TNF-α treatment (n = 7). (* p < 0.05 from TNF-α, # p < 
0.05 from control). One-way ANOVA with Fisher's PLSD 
test.
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Several studies have indicated that T helper (Th1) im-
mune response has important roles in the development of
IBD [48–50]. Moreover, dysregulation of cytokine net-
works is involved in Th1-dominant immune responses in
IBD [48–50]. Among the Th1 cytokines, TNF-α is thought
to be perhaps the most important cytokine responsible for
driving the onset and evolution of IBD. Because of this
prime role of TNF-α in IBD, anti-TNF-α antibody therapy
has been very successfully used in IBD to reduce both co-
lonic injury and expression of ECAMs in IBD [51].
IL-10, a cytokine produced by activated macrophages and
Th2-type T cells, has crucial inhibitory effect against sever-
al Th-1 type immune responses, such as the antigen-pre-
senting functions of monocytes and macrophages
[52,53]. IL-10 may play an important role in preventing
the induction of IBD, since animals deficient in IL-10 will
develop colitis spontaneously, and low levels of IL-10 are
positively correlated with recurrences of Crohn's disease
[25,54]. However, unlike TNF-α based therapies, the ad-
ministration of recombinant IL-10 (rIL-10) shows poor
clinical efficacy. This may reflect the fact that TNF-α
therapies for IBD are aimed at efficiently clearing TNF-α,
while IL-10 therapies must increase  IL-10 and recom-
binant IL-10 is likely too rapidly cleared from the circula-
tion after in vivo administration to provide a uniform
protection [55]. On the other hand, IL-10 gene transfer
technology has been used with some success in models of
colitis, however its effectiveness is also variable. One rea-
son for this variability may be that the final serum IL-10
concentration of gene-transfected mice might be below
the critical threshold needed for gut protection [55,56].
Therefore targeting of the IL-10 gene to the inflamed co-
lon should ideally exploit tissue (i.e. gut) specific promot-
ers to control selective organ gene transfer technology,
endothelial specific promoters and also organ specific in-
tra-arterial injection of vector to activate some genes in
specific locations [57].
Administration of IL-10 in vitro prevents TNF-α stimulated
expression of MAdCAM-1, and also blocks lymphocyte
adhesion to endothelial cells to the same extent as
dexamethasone treatment, currently a key therapy in IBD
[5]. Interestingly, the low basal levels of MAdCAM-1 ex-
pressed by control (cytokine unstimulated) cells were not
affected by IL-10 transfection. This suggests that basal ex-
pression of MAdCAM-1, is IL-10 independent, while cy-
tokine stimulated MAdCAM-1 is  modulated by IL-10.
While we previously showed that delivery of IL-10 to the
endothelium in vitro is protective against TNF-α [5], in vivo
IL-10 has not been as effective. There are at least two reg-
ulating pathways in ECAM expression, one is a cytokine-
dependent pathway which is widely studied and the other
is cytokine-independent [58]. IL-10 apparently prevents
cytokine-induced NF-kB binding activity to the ECAM
promoter [59] and blocks the excessive expression of
ECAMs in cytokine-mediated inflammatory conditions.
In this regard, IL-10 has been used as a treatment in in-
flammatory diseases, like IBD for precisely this reason: be-
cause it has few effects at sites remote from inflammation.
Similarly, we found that IL-10 transfection did not affect
cell morphology, total protein level, or the expression of
actin and vimentin in these cells (measured by Ponceau
red S staining density on immunoblots). Therefore meth-
ods like endothelial gene transfection/transfer in vivo may
effectively maintain adequate IL-10 concentrations near
the endothelial cells that finally achieve the protection
against cytokines that is not uniformly produced by sys-
temic IL-10 administration.
The most important index for how well gene mediated re-
combinant IL-10 delivery might work in IBD appears to
be measurement of the inhibition of lymphocyte-en-
dothelium binding mediated by TNF-α induced MAd-
CAM-1 expression. In this experiment, IL-10 induction in
the endothelium efficiently blocked TNF-α induced MAd-
CAM-1 expression and α4β7-dependent lymphocyte ad-
hesion on SVEC endothelial cells. IL-10 deficiency in
colitis increases expression of several ECAMs including
ICAM-1, VCAM-1 and MAdCAM-1 [60]. We performed an
experiment, where under non-stimulated conditions only
55.7 ± 5.4% as many of the TK-1 lymphocytes bound to
SVEC compared to TNF-α stimulation (100%, or 'maxi-
mal' binding). TK-1 were seen to interact with SVEC
through ICAM-1 as well MAdCAM-1, but not VCAM-1,
since an antibody against MAdCAM-1 reduced adhesion
to 27 ± 4.6% of maximum and an anti-ICAM-1 reduced
adhesion to 54.6 ± 8.3 % of maximum; anti-VCAM-1 re-
duced adhesion to 91% of maximum (blocks lymphocyte
adhesion to endothelial cells (data not shown). Therefore
we feel that adhesion in this system is mostly MAdCAM-1
dependent.
IL-10 transfection of endothelial cells reduced MAdCAM-
1 expression by 42% (following TNF-α stimulation) and
reduced TK-1 adhesion by 50%. Therefore, these data sug-
gest that the reduction of TK-1 adhesion is approximately
84% (42%/50%) MAdCAM-1 dependent, and that the re-
maining 16% of adhesion depends on other ECAMs,
(such as ICAM-1).
Although tissue specific promoters might further increase
the organ specificity and transgene delivery of this ap-
proach, they have not been evaluated in this report. Our
findings suggest that lymphatic or gut endothelial trans-
fection with Th2 cytokines like IL-10 may be an effective
method to reduce important clinical symptoms associated
with IBD which are mediated by MAdCAM-1 dependent
lymphocyte adhesion.BMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/3
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MAdCAM-1 (mucosal addressin cell adhesion molecule-
1), IL-10 (Interleukin-10), HEV (high endothelial venu-
lar), ECAMs (endothelial cell adhesion molecules), IBD
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CD (Crohn's disease), ICAM-1 (intracellular adhesion
molecule 1), VCAM-1 (vascular adhesion molecule 1),
NF-kB (nuclear transfection factor kB), TNF-α (tumor
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stimulating factor), ECL (enhanced chemiluminescence)
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